Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 7, 2004, Pages 473-483

  Phillips, Gordon L ^a,b,e   Meisenberg, B ^b   Reece, D E ^a   Adams, V R ^a   Badros, A ^b   Brunner, J ^c   Fenton, R ^b   Filicko, J ^c   Grosso, D ^c   Hale, G A ^a   Howard, D S ^a   Johnson, V P ^d   Kniska, A ^a,b   Marshall, K W ^a   Nath, R ^a   Reed, E ^a,d   Rapoport, A P ^b   Takebe, N ^b   Vesole, D H ^d   Wagner, J L ^c   Flomenberg, N ^c   more..

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Amifostine; Autologous hematopoietic stem cell transplantation; Escalating dose melphalan; Regimen related toxicity

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; BUSULFAN; CALCIUM SALT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOPERAMIDE; MELPHALAN; METOCLOPRAMIDE; OPIATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPIRATION PNEUMONIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW DEPRESSION; CARDIOMYOPATHY; CARDIOTOXICITY; CELL PROTECTION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG MEGADOSE; DRUG MIXTURE; DRUG SOLUTION; DRUG STABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HODGKIN DISEASE; HUMAN; HYPOCALCEMIA; HYPOTENSION; LEUKOPENIA; LIVER NECROSIS; LUNG HEMORRHAGE; LUNG INSUFFICIENCY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PAIN; PANCYTOPENIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIDE EFFECT; SNEEZING; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; ULCER;

ADULT; AGED; AMIFOSTINE; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG TOXICITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELPHALAN; MIDDLE AGED; NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 2942676796     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.03.001     Document Type: Article

References (44)

1. Herzig G.P. Herzig R.H. Current concepts in dose intensity and marrow transplantation Gale R.P. Acute Myelogenous Leukemia: Progress and Controversies 1990 333-334 Wiley-LissNew York Proceedings of a Wyeth-Ayerst-UCLA Symposia Western Workshop Held at Lake Lanier, Georgia, November 28-December 1, 1989
2. Frei E. III. Teicher B.A. Holden S.A. et al. Preclinical studies and clinical correlation of the effect of alkylating dose Cancer Res. 48 1988 6417-6423
3. Frei E. III. Canellos G.P. Dose: a critical factor in cancer chemotherapy Am J Med. 69 1980 585-594
4. Klingemann H.G. Shepherd J.D. Reece D.E. et al. Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies Bone Marrow Transplant. 14suppl 4 1994 S14-S18
5. Clift R.A. Buckner C.D. Appelbaum F.R. et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens Blood 77 1991 1660-1665
6. Sarosy G. Leyland-Jones B. Soochan P. et al. The systemic administration of intravenous melphalan J Clin Oncol. 6 1988 1768-1782
7. McElwain T.J. Selby P.J. Gore M.E. et al. High-dose chemotherapy and autologous bone marrow transplantation for myeloma Eur J Haematol Suppl. 51 1989 152-156
8. Samuels B.L. Bitran J.D. High-dose intravenous melphalan: a review J Clin Oncol. 13 1995 1786-1799
9. Lazarus H.M. Herzig R.H. Graham-Pole J. et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer J Clin Oncol. 1 1983 701-705
10. 2 melphalan followed by autologous stem cell transplantation in patients with advanced hematological malignancies : pharmacokinetics and toxicity Br J Haematol. 95 1996 527-530
11. Schuchter L.M. Hensley M.L. Meropol N.J. Winer E.P. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol. 20 2002 2895-2903
12. Capizzi R.L. Oster W. Chemoprotective and radioprotective effects of amifostine : an update on clinical trials Int J Hematol. 72 2000 425-435
13. Capelli D. Santini G. de Souza C. et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study Br J Haematol. 110 2000 300-307
14. Chauncey T.R. Gooley T.A. Lloid M.E. et al. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation Am J Clin Oncol. 23 2000 406-411
15. Cronin S. Uberti J.P. Ayash L.J. Raith C. Ratanatharathorn V. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation Bone Marrow Transplant. 26 2000 1247-1249
16. Renner S. Krumpelmann S. Bruchelt G. Wiesinger H. Niethammer D. Klingebiel T. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations Anticancer Res. 20 2000 4531-4538
17. Hartmann J.T. von Vangerow A. Fels L.M. et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation Br J Cancer. 84 2001 313-320
18. Thieblemont C. Dumontet C. Saad H. et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma Bone Marrow Transplant 30 2002 769-775
19. Jantunen E. Kuittien T. Nousiaien T. A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients Leuk Lymphoma. 43 2002 1961-1965
20. Bearman S.I. Appelbaum F.R. Back A. et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma J Clin Oncol. 7 1989 1288-1294
21. Sonis S.T. Eilers J.P. Epstein J.B. et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy Cancer 85 1999 2103-2113
22. Kaplan F.L. Meier P. Nonparametric estimation from incomplete observations J Am Stat Assoc. 52 1958 457-481
23. Adams V.R. Phillips G.L. Hale G.A. et al. Pharmacokinetics and toxicity of escalating doses of melphalan (MEL) given with amifostine (AMI) cytoprotection (CP) in autologous hematopoietic stem cell transplantation (AHSCT): a phase I-II study Proc Am Soc Clin Oncol. 18 2000 A920 (abstr.)
24. Stockerl-Goldstein K.E. Reddy S.A. Horning S.F. et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells Biol Blood Marrow Transplant 6 2000 506-512
25. Phillips G.L. Hale G.A. Howard D.S. et al. G-CSF primed autologous marrow harvest and transplantation in cytapheresis "mobilization failure" patients: a descriptive analysis; bone marrow transplantation Hematology 5 2000 223-231
26. Glover D. Riley L. Carmichael K. et al. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent) N Engl J Med. 309 1983 1137-1141
27. Blume K.G. Thomas E.D. A review of autologous hematopoietic cell transplantation Biol Blood Marrow Transplant 6 2000 1-12
28. Lee S.J. Klar N. Weeks J.C. Antin J.H. Predicting costs of stem-cell transplantation J Clin Oncol. 18 2000 64-71
29. Brockstein B.E. Smiley C. Al-Sadir J. Williams S.F. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors Bone Marrow Transplant 25 2000 885-994
30. Millar J.L. McElwain T.J. Clutterbuck R.D. Wist E.A. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721) Am J Clin Oncol. 5 1982 321-328
31. Spencer C.M. Goa K.L. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector Drugs 50 1995 1001-1031
32. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies to amifostine Semin Oncol. 26 2 suppl 7 1999 3-21
33. Singhal S. Powles R. Treleaven J. Horton C. Swansbury G.J. Mehta J. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women Bone Marrow Transplant 18 1996 1049-1055
34. Jost L.M. Overdose with melphalan (Alkeran): symptoms and treatment. A review Onkologie. 13 1990 96-101
35. Curly C.R. Spencer C.M. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome Drugs. 61 2001 641-684
36. Buschini A. Anceschi E. Carlo-Stella C. et al. Amifostine (WR-2721) selective protection against melphalan genotoxicity Leukemia. 14 2000 1642-1651
37. Dorr R.T. Holmes B.C. Dosing considerations with amifostine: a review of the literature and clinical experience Semin Oncol. 262 suppl 7 1999 108-119
38. Oliveri A. Corvatta L. Montanari M. et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells Bone Marrow Transplant 21 1998 1049-1053
39. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma Bone Marrow Transplant. 23 1999 1003-1006
40. North S. El-Ghissassi F. Pluquet O. Verhaegh G. Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway Oncogene. 19 2000 1206-1214
41. Cassatt D. Extended window of mucosal radioprotection with intravenous or subcutaneous amifostine (Ethyol®) in rats Proc Am Soc Clin Oncol. 19 2001 A1114 (abstr.)
42. Romano M.F. Lamberti A. Bisogni R. et al. Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors Blood. 94 1999 4060-4066
43. Pagel J.M. Matthews D.C. Appelbaum F.R. Bernstein I.D. Press O.W. The use of radioimmunoconjugates in stem cell transplantation Bone Marrow Transplant 29 2002 807-816
44. Phillips K.A. Tannock I.F. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy J Clin Oncol. 16 1998 3179-3190